Skip to search formSkip to main contentSkip to account menu

ARQ 501

Known as: ARQ501 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

beta-lapachone

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Abstract 5369: Prostate cancer radiosensitization through PARP-1 hyperactivation
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL The clinical experimental agent, beta-lapachone (Arq… 
2010
2010
Abstract 3948: Identification of phosphorylated NF45 (T388) as a potential pharmacodynamic biomarker for ARQ 501 (β-lapachone)
2006
2006
A phase Ib trial of ARQ 501, a selective checkpoint activator, in combination with docetaxel in patients with advanced solid tumors.
13053 Background: ARQ 501 is a DNA damage checkpoint activator. It directly activates DNA damage response pathways without… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)